OncoMatch/Clinical Trials/NCT07152288
Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HSK39297 in Subjects With Hepatic Impairment
Is NCT07152288 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including HSK39297 tablets and HSK39297 tablets for paroxysmal nocturnal hemoglobinuria (pnh).
Treatment: HSK39297 tablets · HSK39297 tablets · HSK39297 tablets — The study is being conducted to compare the pharmacokinetics, safety, and pharmacodynamics of HSK39297 in subjects with mild to moderate hepatic impairment and normal hepatic function
Check if I qualifyExtracted eligibility criteria
Lab requirements
Blood counts
hemoglobin (Hb) > 70 g/L; platelet level > 30×10⁹/L (except for those judged by the investigator to be in a stable state)
Kidney function
Glomerular filtration rate (eGFR) ≥75 mL/min/1.73m2 calculated using the CKD-EPI formula
Liver function
Child-Pugh classification of Class A or B (without the use of albumin within 14 days), chronic liver injury caused by previous primary liver diseases, including but not limited to non-alcoholic steatohepatitis, viral hepatitis (hepatitis B, hepatitis C), etc.
Glomerular filtration rate (eGFR) ≥75 mL/min/1.73m2 ... hemoglobin (Hb) ≤ 70 g/L; ... platelet level ≤30×10⁹/L ... Child-Pugh classification of Class A or B ...
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify